Development stage biopharmaceutical company AzurRx BioPharma, Inc. (NASDAQ: AZRX) this morning announced that the United States Patent and Trademark Office has published patent application number 15/519424, entitled ‘Hybrid Proteinaceous Molecule Capable of Inhibiting at Least One Antibiotic and Pharmaceutical Composition Containing It’, covering the company’s AZX1101 recombinant enzyme for the prevention of antibiotic-induced diarrhea and hospital-acquired C. difficile infections. “We believe that AZX1101, a non-systemic protein, can preserve healthy gastrointestinal flora by inhibiting antibiotics in the GI tract and thus prevent the development of antibiotic induced diarrhea and bacterial infections,” Thijs Spoor, CEO of AzurRx, stated in the news release. “We think the drug has particular application in its potential to greatly reduce the number of C. difficile infections.”
To view the full press release, visit http://dtn.fm/KuOo0
About AzurRx BioPharma, Inc.
AzurRx BioPharma, Inc. (NASDAQ: AZRX) is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. MS1819 recombinant lipase for exocrine pancreatic insufficiency is the company’s lead development program, and additional early stage research is being conducted for the prevention of hospital-acquired infections. The company is headquartered in Brooklyn, NY, with scientific operations based in Langlade, France. Additional information on the company can be found at www.AzurRx.com
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
